Perrigo Board unanimously rejects unsolicited US$29bn bid from Mylan

Published: 22-Apr-2015
Finance

Says it substantially undervalues the company and ignores key factors


Perrigo said its Board of Directors has unanimously rejected the unsolicited takeover bid from Mylan, saying it 'substantially undervalues the company and its future growth prospects'.

Earlier this month Mylan offered to buy Perrigo for $205 per share in cash and stock.

Joseph Papa, Chairman, President and CEO of Perrigo, said Mylan had not taken key factors into account, including its global distribution platform, innovative new product pipeline, which is expected to generate nearly $1bn in net sales over the next three years, and the full benefits of the Omega Pharma acquisition, which closed on 30 March.

  • Companies:
  • Perrigo
See more

You may also like

Media

Hikma enters into licensing partnership with Perrigo in MENA

Read more
The partnership will provide significant collaboration opportunity

Trending Articles

  1. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated
  2. Policy vacuum risks UK becoming a medicines supply backwater The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
  3. Abzena develops new facilities in Cambridge, UK and San Diego Abzena, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, provides an update on its UK and US facilities
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    The pros and cons of distribution agreements For life sciences companies seeking to break into overseas markets, distribution agreements are central to success
  5. Wacker strengthens its pharmaceutical-protein business and buys Dutch biotech plant Wacker Chemie AG has acquired a Dutch site to manufacture biopharmaceuticals, live microbial products and vaccines, plus the associated business, from SynCo Bio Luxembourg Sàrl

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Media

Hikma enters into licensing partnership with Perrigo in MENA

The partnership will provide significant collaboration opportunity
Finance

Mylan fails in US$26bn hostile takeover bid for Perrigo

Not enough shareholders supported the deal
Finance

Perrigo to acquire OTC brands from GSK

In the areas of nicotine replacement therapy, cold and flu, and cold sore management
Drug Delivery

Perrigo acquires Patheon's Mexican operations for US$34m

Strengthening its capabilities with the addition of softgel manufacturing technology
Finance

Mylan offers to buy Perrigo for US$29bn

The combination would have 'critical mass' in speciality brands, generics, OTC and nutritional products
Finance

Perrigo to purchase Omega Pharma for €3.6bn

Expanding its over-the-counter product portfolio
Finance

Perrigo to buy Elan for US$8.6bn

Will form a new company incorporated in Ireland to be called Perrigo Company plc or a variant thereof
Subscribe now